Please share...
(Reuters) – U.S. drugmaker AbbVie is betting on the potential of the body’s immune system to fight Alzheimer’s by signing a drug development deal worth more than $ 200 million with unlisted biotech company Alector.
AbbVie bets on Alzheimer’s immunotherapy with big biotech deal
October 24, 2017By
